06/05/2026
The new, temporary Medicare GLP-1 Bridge program will expand affordable access to certain weight-loss medications for eligible Medicare beneficiaries.
It starts July 1, 2026 and is set to run through Dec. 31, 2027. The program has the potential to make a real difference in removing barriers to proven obesity treatment.
Why GLP-1 medications matter
GLP-1 medications, or glucagon-like peptide-1 receptor agonists, were originally developed to help patients manage Type 2 diabetes. Over time, researchers discovered these medicines could also help regulate appetite, reduce cravings, slow digestion, and support significant weight loss, and improve health outcomes.
Today, these medications, such as Wegovy, Ozempic, and Zepbound, have become central to modern obesity treatment and are common household names. Clinical studies show that many patients lose substantial amounts of body weight while taking these medications and following important steps to stay physically active, eat right, and get enough sleep.
For those who live with obesity, weight reduction can improve mobility, decrease joint pain, lower blood pressure, improve blood sugar control, and reduce cardiovascular risk. Some evidence also suggests GLP-1 medications may help lower the risk of heart attacks and strokes in certain patients with obesity and heart disease.
But access has remained difficult because of cost.
How the Medicare GLP-1 Bridge program works
The program creates a pathway for eligible Medicare beneficiaries to access GLP-1 medications at reduced costs while federal officials continue evaluating broader coverage policies.
Under the initiative:
Participating manufacturers will provide GLP-1 medications at a reduced net price of approximately $245 per month.
Eligible beneficiaries will generally pay about $50 per monthly prescription.
This is a meaningful reduction compared to current retail prices and makes a big difference to older adults living on a fixed income.
Officials with the Centers for Medicare and Medcaid Services (CMS) are calling the program a "bridge" to the BALANCE Model, which stands for Better Approaches to Lifestyle and Nutrition for hEalth.
"As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors," according to a CMS webpage.
Who Is eligible for the Medicare GLP-1 Bridge?
Not every Medicare beneficiary will automatically qualify for the bridge program. Eligibility will depend on medical necessity and provider documentation. Health care providers must verify that patients have obesity along with qualifying health conditions that may include:
Heart failure
Prediabetes
Cardiovascular disease
Type 2 diabetes
Hypertension
Sleep apnea
Patients will likely need ongoing medical supervision while taking these medications. Providers may monitor:
Weight changes
Blood sugar levels
Cardiovascular health
Kidney function
Medication side effects
This oversight underscores the importance that obesity treatment should involve comprehensive medical care rather than simply prescribing medication alone, according to CMS.
What are the criteria for accessing the Medicare GLP-1 Bridge?
Under the new program, health care providers may prescribe GLP-1 drugs for obesity so long as patients meet eligibility requirements, such as:
A body mass index (BMI) of 35 or higher
A BMI of 30 or higher as well as diagnosed heart failure, uncontrolled hypertension, or kidney disease
A BMI of 27 or higher as well as previous stroke, prediabetes, a previous heart attack, or peripheral artery disease
Patients must be enrolled in a Medicare Part D or Medicare Advantage plan to access the temporary GLP-1 benefit. And a doctor must submit a prior authorization request to a central processing center, confirming the patient has received counseling on lifestyle changes while taking GLP-1 drugs. Patients can fill their prescription once the request is approved and the pharmacy is notified.
What are potential risks for older adults?
Older adults may face concerns because rapid weight loss can sometimes contribute to muscle loss, weakness, or nutritional deficiencies if not carefully managed.
Patients with certain conditions, including severe gastrointestinal disorders, pancreatitis history, or kidney disease, may require additional evaluation before starting treatment.
Experts recommend combining medication use with:
Balanced nutrition
Adequate protein intake
Strength-building exercise
Regular medical monitoring
This is especially important for older adults seeking to preserve muscle mass and physical independence while losing weight.
Which GLP-1 drugs are included?
The Bridge program won’t include all GLP-1 drugs, according to Medicare. Only Foundayo (a new GLP-1 pill from Eli Lilly), Wegovy (both injectables and oral pills), and the Zepbound KwikPen will be covered.
What older adults should do now
Beneficiaries can begin by discussing obesity treatment options with their health care providers.
Important questions to ask include:
Do I meet likely eligibility requirements?
Which GLP-1 medication may be appropriate for me?
What side effects should I expect?
How will treatment affect my other medications?
What costs will I be responsible for?
Will I need ongoing monitoring or nutrition counseling?
For older adults, however, the message is becoming clearer: obesity treatment is entering a new era. The GLP-1 Bridge program may not solve every challenge. But it represents an important step toward expanding access to potentially life-changing therapies for millions of Medicare beneficiaries.
